Roth CH Acquisition Co. Class A Ordinary Shares
USCT
USCT was delisted on the 24th of April, 2024.
0 hedge funds and large institutions have $0 invested in Roth CH Acquisition Co. Class A Ordinary Shares in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 11 closing their positions.
100% less funds holding
Funds holding: 11 → 0 (-11)
100% less capital invested
Capital invested by funds: $19.9M → $0 (-$19.9M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 11
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
-$3.39M |
| 2 |
CAC
Cowen and Company
New York
|
-$3.09M |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$2.94M |
| 4 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$2.89M |
| 5 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$2.72M |
USCT Hedge Fund Activity: Q2 2024 in Review
0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Roth CH Acquisition Co. Class A Ordinary Shares (USCT) for Q2 2024, worth a combined $0 — down 100% from $19.9M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of USCT and 0 opened new positions — a net loss of 11 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Westchester Capital Management (New York), exiting entirely with an estimated $3.39M sold.
- 0 institutional investors held Roth CH Acquisition Co. Class A Ordinary Shares (USCT) as of Q2 2024, down from 11 in Q1 2024.
- Funds reported $0 of Roth CH Acquisition Co. Class A Ordinary Shares stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new Roth CH Acquisition Co. Class A Ordinary Shares positions in Q2 2024 and 11 closed out, a net change of -11 holders.
- The largest Roth CH Acquisition Co. Class A Ordinary Shares seller in Q2 2024 was Westchester Capital Management (New York), an estimated $3.39M sold.
Based on aggregated 13F filings for Q2 2024.